tlgs: tlgs Data from Tehran Lipid and Glocuse Study.

In faridehbagherzadeh/VariableSelection: Identify the appropriate set of predictors of a binary outcome of interest for diagnostic/ptognostic situations

Description

This is a stratified subsample of pre-diabetic women, aged 20 years and over from the TLGS cohort to predict diabetes outcome. The original data contains hundreds of variables of which 11 are included in this package. Details of the TLGS design have been published before (Azizi and et al. (2000, 2002, 2009)); briefly, it is a population based study performed on a representative sample of residents of Tehran (n=15005, aged ≥ 3yrs), who entered the first phase of the study in 1999-2001. Data on subjects was collected through interview, physical examination and blood sampling at baseline, a process which was repeated every three years; in the second phase, 3500 new subjects were added to the study and followed for the two next phases. Pre-diabetes was defined based on fasting plasma glucose (FPG) ≥ 100 and FPG ≤ 126 mg /dl or 2h post-challenge plasma glucose (2h PG) ≥ 140 and 2h PG ≤ 200 mg/dl. Study subjects taking anti-diabetic drugs at baseline were excluded from the study. Type 2 diabetics included subjects with FPG ≥ 126 or 2h PG ≥ 200 or taking anti-diabetic medication in any follow-up period.

Usage

data(tlgs)

Format

A data frame with 100 observations (35 diabetic, 65 nondiabetic). There are 11 predictor variables measured for each individual.

Outcome

Outcome ("diabetic", "nondiabetic").

Age

Age (years).

Allsty

Total length of residence in Tehran (years).

Bs2hr

2-h post-challange plasma glucose (mg/dl).

TC

Total cholesterol (mg/dl).

Cr

Creatinine (mg/dl).

FPG

Fasting plasma glucose (mg/dl).

HDL-C

High density lipoprotein cholesterol (mg/dl).

Height

Height (cm).

HipC

Hip circumference (cm).

Acedrg

Use of angiotensin-converting-enzyme (ACE) inhibitor drugs.

DBP

Diastolic blood pressure (mm Hg).

Source

Azizi, F., Madjid, M., Rahmani, M., Emami, H., Mirmiran, P. A. R. V. I. N., & Hadjipour, R. (2000). Tehran Lipid and Glucose Study (TLGS): rationale and design. Iranian journal of endocrinology and metabolism, 2(2), 77–86.

Azizi, F., Rahmani, M., Emami, H., Mirmiran, P. A. R. V. I. N., Hajipour, R., Madjid, M., ... & Moeini, S. (2002). Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Sozial-und praventivmedizin, 47(6), 408–426.

Azizi, F., Ghanbarian, A., Momenan, A. A., Hadaegh, F., Mirmiran, P., Hedayati, M., ... & Zahedi-Asl, S. (2009). Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials, 10(1), 5.

References

Azizi, F., Madjid, M., Rahmani, M., Emami, H., Mirmiran, P. A. R. V. I. N., & Hadjipour, R. (2000). Tehran Lipid and Glucose Study (TLGS): rationale and design. Iranian journal of endocrinology and metabolism, 2(2), 77–86.

Azizi, F., Rahmani, M., Emami, H., Mirmiran, P. A. R. V. I. N., Hajipour, R., Madjid, M., ... & Moeini, S. (2002). Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Sozial-und praventivmedizin, 47(6), 408–426.

Azizi, F., Ghanbarian, A., Momenan, A. A., Hadaegh, F., Mirmiran, P., Hedayati, M., ... & Zahedi-Asl, S. (2009). Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials, 10(1), 5.

Examples

library(VariableSelection)
 data(tlgs)
 summary(tlgs)

faridehbagherzadeh/VariableSelection documentation built on May 16, 2019, 10:10 a.m.